Clinical Trial

IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, antineoplastic activity, immunogenicity, pharmacokinetics and pharmacodynamics of IKS03, a CD19 targeting antibody-drug conjugate, in patients with advanced B cell non-Hodgkin lymphoma (NHL).
Protocol Amendment History 2 changes
critical Primary endpoint(s) modified 2026-07-30
notable Primary completion pushed: 2026-09 -> 2027-09 2026-07-30
Trial Details
NCT Number NCT05365659
Lead Sponsor Iksuda Therapeutics Ltd.
Conditions B-cell Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, B-cell Lymphoma
Enrollment 140 participants
Start Date 2023-09-05
Primary Completion 2027-09 (estimated)
Study Completion 2028-09 (estimated)
Updated on ClinicalTrials.gov 2026-07-29